Pomalyst® (pomalidomide): New important advice- Hepatitis B Virus status to be established before initiating treatment with pomalidomide

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

Date: 19 January 2017

 

Description:

Reactivation of hepatitis B has been reported rarely following treatment with pomalidomide plus dexamethasone in patients previously infected with the hepatitis B virus (HBV). HBV status should be established before treatment with pomalidomide is initiated. A Direct Healthcare Professional Communication (DHPC) has been issued by Celgene Sdn. Bhd. in agreement with NPRA to highlight this information. Please refer to this DHPC for further information.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA